Fundraising FoxDomain Associates — 2010 Investments
5 investments dated 2010 · listed companies and verified rows first · show all
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)inFrederic Chereau(Executive Officer)
BoardAmir Nashat(Non-Management Director)inAkkaraju Srinivas(Non-Management Director)
Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesDomain PartnersPolaris PartnersSamsara BioCapital+1 more
Veracyte develops genomic diagnostic tests for cancer, offering laboratory developed tests for thyroid, prostate, bladder, and breast cancers performed in its CLIA-certified, high-complexity labs.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Bonnie H. Anderson(Executive Officer, Director)inJulie Brooks(Executive Officer)inShelly D. Guyer(Executive Officer)inMarc Stapley(Chief Executive Officer)in
BoardSamuel D. Colella(Director)Fred E. Cohen(Director)
Co-investorsCatalyst Health VenturesKleiner Perkins
Achillion conducts research and development focused on addressing rare disease challenges through investigation of new therapeutic targets, modalities, and technologies.
BiotechHealthtech
Co-investorsConnecticut InnovationsPappas CapitalSV Health Investors
bioMérieux develops in vitro diagnostic systems and molecular testing panels for pathogen detection in clinical, food safety, and pharmaceutical quality control settings.
BiotechHealthtechMedical DevicesSan Diego, US
Todd Myers(Executive Officer)inChristopher Hibberd(Executive Officer, Director)Kenneth Buechler(Director)Paul McPherson(Executive Officer, Director)
BoardJames Blair(Director)James Scopa(Director)
Co-investorsKaiser Permanente VenturesMoore Venture Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Otonomy
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.